Presentation

Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use

World Health Organization (WHO)

Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use

Authors

Languages

  • English

Publication year

2025

Type

Presentation

Categories

  • Vaccines & delivery devices

Diseases

  • Mpox

Organisations

  • World Health Organization (WHO)

Tags

  • SAGE

Topic references

Mpox-Policy

TitleAuthorYearTypeLanguage
Vaccin contre la variole et la mpox MVA-BN (‎Modified Vaccinia Ankara - Bavarian Nordic)‎ : directives provisoiresWorld Health Organization (WHO)2024GuidanceFrench
ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of ageEuropean Medicines Agency2024GuidanceEnglish
LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim GuidanceWorld Health Organization (WHO)2025GuidanceEnglish
MVA-BN (‎Modified Vaccinia Ankara – Bavarian Nordic)‎ smallpox and mpox vaccine: Interim guidanceWorld Health Organization (WHO)2024GuidanceEnglish
Note de synthèse: position de l’OMS sur les vaccins contre la variole et la mpox (orthopoxvirus)World Health Organization (WHO)2024GuidanceFrench
Off-label vaccine use: explanatory note for countriesWorld Health Organization (WHO)2024GuidanceEnglish
Regulatory & Policy Considerations for Mpox Vaccines in African CountriesWorld Health Organization (WHO), European Medicines Agency, Bavarian Nordic2025PresentationEnglish
Smallpox and mpox (orthopoxviruses): WHO position paperWorld Health Organization (WHO)2024GuidanceEnglish
Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label useWorld Health Organization (WHO)2025PresentationEnglish

Added by: Alba Vilajeliu

Added on: 2024-11-19 15:06:01

Hits: 439

Links

Uploaded file

1. WHO_MVA-BN vaccine recommendations_March2025.pptx

Click to Download

Add resource